HEALTHQUARTZ
FDA picks Eli Lilly and Regeneron for program to speed up domestic drug factory reviews
The FDA has selected Eli Lilly and Regeneron for its PreCheck program, which aims to expedite domestic drug factory reviews by assessing facilities during construction. The program could save participating companies up to 14 months in review time.
Related Signal
Adjacent reporting
- Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
- A new FDA strategy aims to get medicines to the market faster
- Canada Aims to Approve Projects in a Year After Criticism It’s Too Slow
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says